{"id":"W2265622440","doi":"10.1200/jco.2012.30.15_suppl.4558","title":"Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"","keywords":"Medicine; Abiraterone acetate; Placebo; Clinical endpoint; Prostate cancer; Internal medicine; Discontinuation; Prednisone; Oncology; Tolerability; Docetaxel; Randomization; Hazard ratio; Urology; Gastroenterology; Randomized controlled trial; Androgen deprivation therapy; Cancer; Confidence interval; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01382341,0.00143743,0.00172979,0.0005785809,0.0002956049,0.0009713707,0.001018986,0.001282527,0.003556529],"category_scores_gemma":[0.01252072,0.0004505734,0.005399179,0.0005409708,0.0009386207,0.0009225844,0.0007297046,0.001929098,0.0003932497],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007502764,"about_ca_system_score_gemma":0.001416494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003533192,"about_ca_topic_score_gemma":0.0006694449,"domain_scores_codex":[0.9924435,0.006030845,0.0002498998,0.0004799593,0.0003768721,0.0004188528],"domain_scores_gemma":[0.9833325,0.0122168,0.001788099,0.00125152,0.0003683303,0.001042801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9377027,0.006650255,0.016774,0.0004539121,0.006387959,0.0002075459,0.0001872412,0.003695403,0.009230948,0.0002329288,0.0006617654,0.01781546],"study_design_scores_gemma":[0.1686121,0.6422015,0.1363591,0.00009077971,0.01718004,0.0005539595,0.0002408333,0.01646549,0.01250619,0.001649904,0.003996813,0.0001432913],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945879,0.001045904,0.001415093,0.0001437233,0.00004379599,0.0008557165,0.0009914328,0.00006092236,0.0008555471],"genre_scores_gemma":[0.995697,0.0001867484,0.001432321,0.0001682316,0.00006253819,0.0007550715,0.000927064,0.00001851515,0.0007524972],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01382341,"threshold_uncertainty_score":0.07310605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2240525746293755,"score_gpt":0.516633520639768,"score_spread":0.2925809460103925,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}